(2001). A new mathematical model for relative quantification in realtime RT-PCR.
(2001). Aikou T: Preserved Smad4 expression in the transforming growth factor beta signaling pathway is a favorable prognostic factor in patients with advanced gastric cancer. Clin Cancer Res
(2002). Aikou T: Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res
(2002). Akhurst RJ, Balmain A: Metastasis is driven by sequential elevation
(2002). Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res
(2003). C: SMAD7 is a prognostic marker in patients with colorectal cancer.
(2010). Chiang KN: Functional interaction between Smad3 and S100A4 (metastatin-1) for TGF-beta-mediated cancer cell invasiveness.
(2007). CS: TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol
(1999). DB: Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle.
(2005). Derynck R: Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol
(2004). development of chemically induced skin tumors in mice. Vet Pathol
(2006). Dysregulated TGF-beta1-induced Smad signalling occurs as a result of defects in multiple components of the TGF-beta signalling pathway in human head and neck carcinoma cell lines.
(2007). Expression and significance of
(2003). Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res
(2008). HG: Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res
(2004). human gastric carcinomas. Ann Oncol
(2003). Imamura T: Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci
(2006). Kähäri VM: Activation of Smad signaling enhances collagenase -3 expression and invasion of head and neck carcinoma cells. Oncogene
(1998). Kawabata M: Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun
(2006). Kuwano H: Lack of activated Smad2 in transforming growth factor-beta signaling is an unfavorable prognostic factor in patients with esophageal squamous cell carcinoma. J Surg Oncol
(2004). Kuwano H: Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGFbeta superfamily, in esophageal squamous cell carcinoma. Anticancer Res
(2001). MH: Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck
(2010). Miyazono K: Cellular context-dependent "colors" of transforming growth factor-b signaling. Cancer Sci
(1997). Miyazono K: Smad6 inhibits signalling by the TGF-beta superfamily. Nature
(2009). Moustakas A: Regulating the stability of TGFbeta receptors and Smads. Cell Res
(2009). Moustakas A: Regulating the stability of TGFβ receptors and Smads. Cell Research
(2001). Muñoz-Antonia T: Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2. Clin Cancer Res
(2008). Pavasant P: TGFbeta1 induced MMP-9 expression in HNSCC cell lines via Smad/MLCK pathway. Biochem Biophys Res Commun
(2007). Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2, N0 tumours. Anticancer Res
(2006). Regulation of Smad activities.
(1996). Saji S: Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology
(1999). Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun
(2007). Su GH: Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett
(1996). T: Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res
(1999). The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene
(2000). Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res
(2008). Violette SM: Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res
(2006). Wong DT: Loss of p12 cd2-ap1 expression in human oral squamous cell carcinoma with disrupted trasnforming growth factor β-Smad signaling patway. Neoplasia
(2009). XF: TGFbetastimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch.